Fig. 3From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysisObjective response rate and disease control rate (a The meta-analysis documented a clear advantage of the cetuximab group over bevacizumab group in the ORR; b No significant differences in the DCR were noticed between the two groups)Back to article page